.png){kind=icon}
返回
Augmenting DMTA using predictive AI modelling at AstraZeneca
.png){kind=icon}
OA
AI
DOI：10.1016/j.drudis.2024.103945.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Design-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insight Platform (PIP), a cloud-native modelling platform developed at AstraZeneca. The impact of PIP in each step of DMTA, as well as its architecture, integration, and usage, are discussed and used to provide insights into the future of drug discovery.
Keyword:
drug discovery
cloud computing
arti ficial intelligence
machine learning
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.5
论文数:
6.4K
被引数:
2.3W
机构
引用论文
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery.png)
DRUG DISCOVERY TODAYOAAI
DRUG DISCOVERY TODAYIF7.5
OAAI分享收藏Implementation and relevance of FAIR data principles in biopharmaceutical R&DDRUG DISCOVERY TODAYOAAI
DRUG DISCOVERY TODAYIF7.5
OAAI分享收藏分享收藏
查看更多内容